LivaNova PLC (LIVN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, LivaNova PLC (LIVN) has a cash flow conversion efficiency ratio of 0.050x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($66.59 Million) by net assets ($1.33 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see LIVN company net worth for the company's overall valuation and market capitalisation.
LivaNova PLC - Cash Flow Conversion Efficiency Trend (1992–2025)
This chart illustrates how LivaNova PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data.
LivaNova PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of LivaNova PLC ranked by their cash flow conversion efficiency. Explore cash flow quality index of LivaNova PLC to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tauron Polska Energia S.A.
WAR:TPE
|
0.065x |
|
LG Uplus
KO:032640
|
0.108x |
|
PEPCO GROUP N.V. EO-01
F:8UX
|
N/A |
|
Edenred SA
PA:EDEN
|
0.129x |
|
GRIFOLS ADR 1/2/EO-50
F:G0F
|
0.057x |
|
Zeta Global Holdings Corp
NYSE:ZETA
|
0.084x |
|
Andon Health Co Ltd
SHE:002432
|
0.024x |
|
Aya Gold & Silver Inc
TO:AYA
|
0.095x |
Annual Cash Flow Conversion Efficiency for LivaNova PLC (1992–2025)
The table below shows the annual cash flow conversion efficiency of LivaNova PLC from 1992 to 2025. View LivaNova PLC (LIVN) stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.20 Billion | $254.30 Million | 0.212x | +52.86% |
| 2024-12-31 | $1.32 Billion | $183.04 Million | 0.139x | +136.44% |
| 2023-12-31 | $1.28 Billion | $74.91 Million | 0.059x | +1.30% |
| 2022-12-31 | $1.21 Billion | $69.90 Million | 0.058x | -26.92% |
| 2021-12-31 | $1.29 Billion | $102.54 Million | 0.079x | +210.66% |
| 2020-12-31 | $1.11 Billion | $-79.40 Million | -0.072x | -8.67% |
| 2019-12-31 | $1.38 Billion | $-91.14 Million | -0.066x | -182.20% |
| 2018-12-31 | $1.50 Billion | $120.50 Million | 0.080x | +59.33% |
| 2017-12-31 | $1.82 Billion | $91.30 Million | 0.050x | -4.82% |
| 2016-12-31 | $1.71 Billion | $90.20 Million | 0.053x | +20.14% |
| 2015-12-31 | $1.81 Billion | $79.68 Million | 0.044x | -78.97% |
| 2014-12-31 | $259.10 Million | $54.20 Million | 0.209x | 0.00% |
| 2013-12-31 | $259.10 Million | $54.20 Million | 0.209x | -39.26% |
| 2012-12-31 | $229.57 Million | $79.05 Million | 0.344x | -15.79% |
| 2011-12-31 | $183.47 Million | $75.03 Million | 0.409x | +43.86% |
| 2010-12-31 | $175.45 Million | $49.87 Million | 0.284x | +14.84% |
| 2009-12-31 | $173.27 Million | $42.89 Million | 0.248x | -0.61% |
| 2008-12-31 | $98.74 Million | $24.59 Million | 0.249x | -73.03% |
| 2007-12-31 | $15.65 Million | $14.46 Million | 0.923x | -33.88% |
| 2006-12-31 | $-14.81 Million | $-20.69 Million | 1.397x | +109.12% |
| 2005-12-31 | $4.63 Million | $-70.88 Million | -15.308x | -29052.47% |
| 2004-12-31 | $75.60 Million | $-3.97 Million | -0.053x | -200.75% |
| 2003-12-31 | $68.98 Million | $3.60 Million | 0.052x | +175.46% |
| 2002-12-31 | $67.42 Million | $1.28 Million | 0.019x | +103.55% |
| 2001-12-31 | $43.02 Million | $-22.95 Million | -0.533x | -77.18% |
| 1999-12-31 | $27.15 Million | $-8.18 Million | -0.301x | +31.59% |
| 1998-12-31 | $33.40 Million | $-14.70 Million | -0.440x | -9.73% |
| 1997-12-31 | $36.90 Million | $-14.80 Million | -0.401x | -63.11% |
| 1996-12-31 | $48.80 Million | $-12.00 Million | -0.246x | +96.16% |
| 1995-12-31 | $1.50 Million | $-9.60 Million | -6.400x | -600.95% |
| 1994-12-31 | $6.90 Million | $-6.30 Million | -0.913x | -201.63% |
| 1993-12-31 | $18.50 Million | $-5.60 Million | -0.303x | -51.98% |
| 1992-12-31 | $24.10 Million | $-4.80 Million | -0.199x | -- |
About LivaNova PLC
LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services. The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessor… Read more